Abstract: Objective To evaluate and forecast the economic outcomes of the national hepatitis B immunoprophylaxis strategies from 2006 to 2030, and to promote a nationwide program eliminating hepatitis B launched early in China. Methods The decision analytic-Markov model was used with newborns from 2006 to 2030 as simulation cohort. The cost-effectiveness and cost-benefit analysis were assessed for different scenarios of the last decade and the next fifteen years. The costs and benefits were calculated from the health-care and societal perspectives. The net benefits (NB) and benefit cost ratio (BCR) were considered indicators of cost-benefit analysis. The numbers of hepatitis B virus(HBV)infection and the patients with HBV-related diseases prevented, cumulative quality adjusted life years (QALYs) and the costs per QALYs gained were calculated for cost-effectiveness analysis. Results From 2006 to 2015, the costs of the strategy from two perspectives were RMB 625.664 billion yuan and 812.503 billion yuan, respectively. However, the NB reached up to RMB 4 357.185 billion yuan and 5 370.380 billion yuan, with the BCR of 7.96 and 7.61, respectively. And the costs per QALYs gained were RMB 6 471.53 yuan and 10 023.55 yuan. A total of 96 million QALYs were gained for all birth cohorts. Although the costs with RMB 750.015 billion yuan and 1 029.086 billion yuan will be invested from 2016 to 2030, the more NB with RMB 7 272.935 billion yuan and 8 981.808 billion yuan, the larger BCR with 9.45 and 8.79 and the more QALYs with 137 million will be gained for the strategy implementing sustainably. Also,the RMB 5 398.36 Yuan and 8 389.38 Yuan will be the costs per QALYs gained. Conclusions The national hepatitis B immunoprophylaxis strategies implemented in the last 10 years are with high value of cost-benefit and cost-effectiveness. The strategies will be gained more in the future 15 years, so as to respond the world health organization(WHO)advocacy for eliminating hepatitis B in China.